http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer.
Keam, Bhumsuk,Im, Seock-Ah,Lim, Yoojoo,Han, Sae-Won,Moon, Hyeong-Gon,Oh, Do-Youn,Cho, Nariya,Lee, Se-Hoon,Han, Wonshik,Moon, Woo Kyung,Kim, Dong-Wan,Kim, Tae-You,Park, In Ae,Noh, Dong-Young Raven Press 2013 Annals of Surgical Oncology Vol.20 No.7
<P>Recently, the American Joint Committee on Cancer (AJCC) 7th edition proposed new response criteria for neoadjuvant chemotherapy (NAC) in breast cancer. The purpose of this study was to evaluate the clinical usefulness of AJCC response criteria.</P>
Keam, Bhumsuk,Im, Seock-Ah,Koh, Youngil,Han, Sae-Won,Oh, Do-Youn,Cho, Nariya,Kim, Jee Hyun,Han, Wonshik,Kang, Keon Wook,Moon, Woo Kyung,Kim, Tae-You,Park, In Ae,Noh, Dong-Young,Chung, June-Key,Bang, Y Maruzen Co 2013 Breast cancer Vol.20 No.2
<P>The purpose of this study was to determine the usefulness of sequential FDG PET/CTs for prediction of axillary lymph node (ALN) status after neoadjuvant chemotherapy (NAC).</P>
In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer.
Keam, Bhumsuk,Kim, Soyeon,Ahn, Yong-Oon,Kim, Tae Min,Lee, Se-Hoon,Kim, Dong-Wan,Heo, Dae Seog Potamitis Press 2015 Anticancer research Vol.35 No.1
<P>The purpose of the present study was to explore the antiproliferative effect of BYL719, a specific inhibitor for phosphatidylinositol 3-kinase (PI3K) p110α, in human head and neck cancer cell lines, as a single agent or in combination with the irreversible EGFR tyrosine kinase inhibitor, dacomitinib.</P>
Dowook Kim(Dowook Kim),Bhumsuk Keam(Bhumsuk Keam),Soon-Hyun Ahn(Soon-Hyun Ahn),Chang Heon Choi(Chang Heon Choi),Hong-Gyun Wu(Hong-Gyun Wu) 대한방사선종양학회 2022 Radiation Oncology Journal Vol.40 No.4
Purpose: Nasopharyngeal cancer (NPC) has a higher prevalence of regional nodal metastasis than other head and neck cancers; however, level IB lymph node involvement is rare. We evaluated the safety and feasibility of level IB-sparing radiotherapy (RT) for NPC patients. Materials and Methods: We retrospectively reviewed 236 patients with NPC who underwent definitive intensity-modulated RT with or without chemotherapy between 2004 and 2018. Of them, 212 received IB-sparing RT, and 24 received non-IB-sparing RT. We conducted a propensity score matching analysis to compare treatment outcomes according to IB-sparing status. In addition, dosimetric analysis of the salivary glands was performed to identify the relationship between xerostomia and the IB-sparing RT. Results: The median follow-up duration was 78 months (range, 7 to 194 months). Local, regional, and distant recurrences were observed in 11.9%, 6.8%, and 16.1% of patients, respectively. Of the 16 patients with regional recurrence, 14 underwent IB-sparing RT. The most common site categorization of regional recurrence was level II (75%), followed by retropharyngeal lymph nodes (43.8%); however, there was no recurrence at level IB. In the matched cohorts, IB-sparing RT was not significantly related to treatment outcomes. However, IB-sparing RT patients received a significantly lower mean ipsilateral and contralateral submandibular glands doses (all, p < 0.001) and had a lower incidence of chronic xerostomia compared with non-IB-sparing RT patients (p = 0.006). Conclusion: Our results demonstrated that IB-sparing RT is sufficiently safe and feasible for treating NPC. To reduce the occurrence of xerostomia, IB-sparing RT should be considered without compromising target coverage.
Tae Hyun Kim(Tae Hyun Kim),Jin Ho Kim(Jin Ho Kim),Chang Hyun Kang(Chang Hyun Kang),Bhumsuk Keam(Bhumsuk Keam),Hak Jae Kim(Hak Jae Kim) 대한방사선종양학회 2024 Radiation Oncology Journal Vol.42 No.1
Although Fanconi anemia patients accompany a high risk of multiple cancers, radiation therapy on these patients has been carried out only in limited cases due to the concern for radiation toxicity that stems from their susceptibility to radiation. We report a case of a 28-year-old female patient diagnosed as synchronous esophageal and tongue cancer, and underwent two cycles of radiation therapy, inevitably in the condition of coronavirus disease 2019 infection. She received radiation therapy of 30 Gy to esophageal mass with neoadjuvant aim in her first-round radiation therapy, and later received 27 Gy to tongue cancer surgical bed with adjuvant aim in her second-round radiation therapy. With no further treatment, she has been maintaining no evidence of disease state for 7 months. Managing Fanconi anemia patients with multiple cancers using radiation therapy is feasible, in which cases a dose de-escalation may be important considering the radiation toxicity and possible future re-treatment.
Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma
Kim, Ryul,Keam, Bhumsuk,Kwon, Dohee,Ock, Chan-Young,Kim, Miso,Kim, Tae Min,Kim, Hak Jae,Jeon, Yoon Kyung,Park, In Kyu,Kang, Chang Hyun,Kim, Dong-Wan,Kim, Young Tae,Heo, Dae Seog Baishideng Publishing Group Inc 2016 WORLD JOURNAL OF GASTROENTEROLOGY Vol.22 No.37
<P><B>AIM</B></P><P>To investigate the expression and prognostic role of programmed death ligand-1 (PD-L1) in locally advanced esophageal squamous cell carcinoma (ESCC).</P><P><B>METHODS</B></P><P>A total of 200 patients with ESCC who underwent radical esophagectomy with standard lymphadenectomy as the initial definitive treatment in Seoul National University Hospital from December 2000 to April 2013 were eligible for this analysis. Tissue microarrays were constructed by collecting tissue cores from surgical specimens, and immunostained with antibodies directed against PD-L1, p16, and c-Met. Medical records were reviewed retrospectively to assess clinical outcomes. Patients were divided into two groups by PD-L1 status, and significant differences in clinicopathologic characteristics between the two groups were assessed.</P><P><B>RESULTS</B></P><P>Tumor tissues from 67 ESCC patients (33.5%) were PD-L1-positive. Positive p16 expression was observed in 21 specimens (10.5%). The H-score for c-Met expression was ≥ 50 in 42 specimens (21.0%). Although PD-L1-positivity was not significantly correlated with any clinical characteristics including age, sex, smoking/alcoholic history, stage, or differentiation, H-scores for c-Met expression were significantly associated with PD-L1-positivity (OR = 2.34, 95%CI: 1.16-4.72, <I>P</I> = 0.017). PD-L1 expression was not significantly associated with a change in overall survival (<I>P</I> = 0.656). In contrast, the locoregional relapse rate tended to increase (<I>P</I> = 0.134), and the distant metastasis rate was significantly increased (HR = 1.72, 95%CI: 1.01-2.79, <I>P</I> = 0.028) in patients with PD-L1-positive ESCC compared to those with PD-L1-negative ESCC.</P><P><B>CONCLUSION</B></P><P>PD-L1 expression is positively correlated with c-Met expression in ESCC. PD-L1 may play a critical role in distant failure and progression of ESCC.</P>